glutathione S-transferase mu 5Genealiases: GSTM5-5 · GTM5
Q-omics provides the consensus-scored GSTM5 profile across patient tissues and cancer cell-line models. GSTM5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GSTM5 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, GSTM5 protein abundance shows 29,359 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight LIHC, BLCA, and UCEC as cancer lineages where GSTM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GSTM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GSTM5 survival associations across molecular data types. GSTM5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GSTM5 RNA expression–survival associations across cancer types. High GSTM5 expression shows unfavorable associations in KIRP and THCA, but favorable associations in LIHC, SARC, BRCA and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for GSTM5 RNA expression.
This table summarizes GSTM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 11. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GSTM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GSTM5 shows lower tumor expression in BLCA, LUAD, THCA, COAD, KIRC and KICH. The BLCA box plot shows higher GSTM5 RNA expression in normal versus tumor tissue (log2 FC = −3.415, t-test p < 0.001).
This table shows molecular features associated with GSTM5 in patient tissues and cancer cell lines. In patient samples, GSTM5 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, GSTM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_SCLC.
